Abstract 14530: Long-Term Risk Reduction of Major Amputation in Patients with Critical Limb Ischemia by Autologus Bone-Marrow Cell Implantation
Background: Autologous bone-marrow mononuclear cell (BM-MNC) implantation increases collateral vessel formation and improves ischemic symptoms in patients with critical limb ischemia. However, there was little information on long-term clinical outcomes after BM-MNC implantation.
Methods and Results: We assessed long-term clinical outcomes after BM-MNC implantation in 50 patients with critical limb ischemia, including 24 patients with PAD and 26 patients with Buerger's disease and 45 critical limb ischemic patients who had no BM-MNC implantation as a control. Median follow-up time was 4.8 years. The 4-year amputation-free rates after BM-MNC implantation were 48% in PAD patients and 95% in Buerger's disease and were 0% in control PAD patients and 6% in control Buerger's disease. The 4-year overall survival rates after BM-MNC implantation were 75% in PAD patients and 100% in Buerger's disease and were 62% in control PAD patients and 100% in control Buerger's disease. Multivariate Cox proportional hazards analysis revealed that BM-MNC implantation, diabetes mellitus and hemodialysis were independent predictors of prevention of major amputation.
Conclusions: These findings may reveal that BM-MNC implantation is safe and effective in patients with critical limb ischemia, especially in Buerger's disease.
- © 2011 by American Heart Association, Inc.